Search

Figure S1. CD8+ cell densities correlate with the presence of McPyV, but PD-1 densities do not correlate with viral status. Figure S2. PD-1+ cell densities in both the peritumoral and intratumoral regions correlate with anti-PD-1 response, but CD8+ cell densities in these regions do not. Figure S3. Pathologist scores for PD-L1 expression levels did not associate with response to anti-PD-1 in patients with MCC. Figure S4. Computer-assisted quantitation of PD-L1 in the PT and IT regions of tumor can help distinguish anti-PD-1 responders (R) from non-responders (NR). Figure S5. CD8+, PD-1+, and PD-L1+ TME cell densities by quartile from MCC patients receiving anti-PD1. Figure S6. The density of PD-L1+ cells adjacent to a PD-1+ cell correlates with clinical response to anti-PD-1. (PDF 611Â kb)

Frequency of tetramer+ CD8 T cells. Frequency of MCPyV tetramer positive CD8 T cells are reported in percent of all CD8s with background subtracted. Abbreviations for RECIST 1.1 response criteria are as follows: CR = complete response; PR = partial response; PD = progressive disease. (DOCX 69 kb)

Class I HLA Tetramers and MCPyV peptide pools. Description of data: A) Summary of HLA and peptide combinations used for CD8 class I tetramers including which position of the MCPyV oncoprotein (small, common, or large T antigen) the peptide corresponds to. B) Schematic of MCPyV peptide pools and locations of tetramer epitopes. Details of peptide pools are available in Iyer et al., 2011. (DOCX 364â kb)

Frequency of IFN-γ and/or IL-2 secreting CD8 T cells in response to Merkel polyomavirus peptide pools. IFN-γ and/or IL-2 in A) 2 of 13 VP-MCC responders and B) 1 of 4 VP-MCC non-responders was detectible via flow cytometry after a 16 h stimulation with MCPyV peptide pools. Dotted line represents background signal cutoff. *Post = first blood draw after initiation of treatment. (DOCX 425 kb)

Frequency of tetramer+ CD8 T cells. Frequency of MCPyV tetramer positive CD8 T cells are reported in percent of all CD8s with background subtracted. Abbreviations for RECIST 1.1 response criteria are as follows: CR = complete response; PR = partial response; PD = progressive disease. (DOCX 69 kb)

Class I HLA Tetramers and MCPyV peptide pools. Description of data: A) Summary of HLA and peptide combinations used for CD8 class I tetramers including which position of the MCPyV oncoprotein (small, common, or large T antigen) the peptide corresponds to. B) Schematic of MCPyV peptide pools and locations of tetramer epitopes. Details of peptide pools are available in Iyer et al., 2011. (DOCX 364â kb)

Serology results. Raw results for MCPyV-specific oncoprotein antibodies were reported as Standard Titer Units (STUs). Patient with a value of 75 or greater were considered oncoprotein antibody producers and values below 74 were considered negative. Abbreviations for RECIST 1.1 response criteria are as follows: CR = complete response; PR = partial response; PD = progressive disease. (DOCX 114 kb)

Serology results. Raw results for MCPyV-specific oncoprotein antibodies were reported as Standard Titer Units (STUs). Patient with a value of 75 or greater were considered oncoprotein antibody producers and values below 74 were considered negative. Abbreviations for RECIST 1.1 response criteria are as follows: CR = complete response; PR = partial response; PD = progressive disease. (DOCX 114 kb)

Frequency of IFN-γ and/or IL-2 secreting CD8 T cells in response to Merkel polyomavirus peptide pools. IFN-γ and/or IL-2 in A) 2 of 13 VP-MCC responders and B) 1 of 4 VP-MCC non-responders was detectible via flow cytometry after a 16 h stimulation with MCPyV peptide pools. Dotted line represents background signal cutoff. *Post = first blood draw after initiation of treatment. (DOCX 425 kb)